
DeepSeek announced on Thursday a “significant” price hike, amid surging global demand for a new ultra-cheap model, which sparked debate over how the Chinese AI start-up has delivered powerful performance at rock-bottom prices.
DeepSeek would raise overall pricing for its application programming interface (API) services “in the near future”, with specific plans to be advised later, the Hangzhou-based company said in a statement on its developer platform on Thursday.
A “significant increase” was expected, and users should plan their usage accordingly, DeepSeek added.
The notice came a week after the release of its latest model DeepSeek-V4-Flash-0731, a 284-billion-parameter lightweight version of the V4 series previewed in April.
DeepSeek’s plans for a major price hike underscore the challenges the Chinese start-up faces to maintain its aggressively low prices amid fierce competition, potentially clouding its reputation for being a champion for cost-effective AI.
“DeepSeek choosing to raise prices at this time – isn’t this just asking for trouble?” Michael Guo, an AI developer, wrote on X on Thursday, arguing that new American models including Meta’s Muse Spark and OpenAI’s GPT-5.6 Luna were competitive with DeepSeek models in both capabilities and price.
DeepSeek’s new model rapidly gained traction in the global AI community for combining near-frontier capabilities with extremely low prices.

Don't Miss:
-
FBI Most Wanted “Chapo Isidro,” Leader of BLO/Guasave Cartel Arrested in Sinaloa, “El Musico” Possibly Killed
-
DEA’s #FugitiveFriday asks for tips on “El Tano” García Corrales, found dead in Sinaloa in 2024
-
Mocorito, Sinaloa: “El Pagador” and “El Chendo” of La FEA, arrested again 15 months after walking free
-
Zapopan: Marines arrest “El Topo,” alleged Los Deltas leader linked to journalist’s kidnapping; three gunmen killed
-
Anabel Hernández claims “El Mayito Gordo” is back in Mexico, fighting Los Chapitos from the Durango sierra

Trump Enjoyed His Asian Spectacle. He Came Home Empty-Handed
Medical device makers have gotten worse at disclosing when their products harm people, new study finds. The FDA let them.
Anatomy of a Chinese loanbook